Clinical Study

Ucci-Hn-17-01

Posted Date: May 15, 2019

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

This is a study using immunotherapy (nivolumab) in patients with recurrent head and neck cancer after failing at least radiation therapy requiring a salvage surgical resection. Patients receive 6 months of monthly nivolumab after surgery in attempt to prevent subsequent recurrence of cancer.

Criteria:

To Be Eligible To Participate In This Study, Patients Must Have Undergone Surgery For Head And Neck Cancer After Failing Radiation Treatment. Patients Must Not Have An Autoimmune Disease Or Require Steroids.

Keywords:

Head And Neck Cancer, Resection, Phase Ii, Ucci-Hn-17-01

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.